Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiontech Se Adr Share News (0A3M)

Share Price Information for Biontech Se Adr (0A3M)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 91.375
Bid: 89.10
Ask: 93.65
Change: 3.70 (4.22%)
Spread: 4.55 (5.107%)
Open: 90.60
High: 91.825
Low: 88.35
Prev. Close: 87.675
0A3M Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EU negotiating boost in Covid-19 doses from Pfizer/BioNTech to 600m

Tue, 05th Jan 2021 12:51

(Sharecast News) - Brussels is negotiating a deal with Pfizer and BioNTech to provide enough Covid-19 vaccine doses to inoculate as much as two-thirds of the bloc's population.
According to Bloomberg, which cited people familiar with the talks, the new contract would be for 100m doses together with an option for a further 200m.

The report comes amid a slower-than-expected approval process for AstraZeneca and Oxford University's vaccine and some criticism regarding the speed at which the new vaccines are being rolled-out across the Continent.

There had also been increasing concern over just the last two weeks around a new Covid-19 strain first detected in the UK which could be roughly 56% more transmissible than those more prevalent in the rest of Europe.

The detection of a possibly even more worrying strain in South Africa was also a source of concern.

For now vaccines were expected to still be effective against the new strains and those based on mRNA technology, such as that from the Pfizer/BioNTech tandem could be modified quickly to address new strains.

Tuesday's news followed the EU's decision just a week before to increase the size of its order from Pfizer-BioNTech from 200m doses to 300m.

Nonetheless, the EU had already inked deals with a range of manufacturers for approximately 2bn vaccine doses - but most had yet to be approved.

When contacted by Bloomberg, BioNTech boss, Ugur Sahin, said: "We are in talks about whether and how we can provide further vaccine doses from Europe for Europe this year."

A spokesman for the firm reportedly declined to comment on the number of doses being talked about.

In December, Sahin had shown confidence in the companies' ability to boost output adding that the exact amount of any production increase would likely be known in January of February.

As of 1246 GMT, shares of BioNTech were advancing by 5.16% to $85.73, but those of Pfizer had dipped 0.16% to $36.75 in pre-market trading.

More News
4 Jun 2021 16:44

UK approves Pfizer-BioNTech Covid-19 vaccine shot for use in 12-15 year olds

(Sharecast News) - Britain has approved the Covid-19 vaccine jointly developed by Pfizer-BioNTech for use in children ages 12 to 15.

Read more
17 Feb 2021 10:19

Pfizer-BioNTech to supply EU with additional 200m doses of Covid-19 vaccine

(Sharecast News) - Pfizer and BioNTech have agreed to supply the European Union with an additional 200 million doses of their Covid-19 vaccine.

Read more
10 Feb 2021 15:30

BioNTech starts Covid-19 vaccine production at new Marburg plant

(Sharecast News) - BioNTech has started production of its Covid-19 vaccine from a new manufacturing site in Marburg, Germany.

Read more
30 Dec 2020 11:51

China's Sinopharm seeks Covid vaccine approval at 79% effectiveness

(Sharecast News) - Chinese Covid-19 vaccine developer Sinopharm said it will seek approval from regulators after final stage trials showed a 79% efficacy rate.

Read more
15 Dec 2020 12:55

WHO claims new loans and bonds could fill $28bn gap for coronavirus funding

(Sharecast News) - The World Health Organization claims that new loans and bonds could help fill a $28bn funding shortfall for combating the coronavirus pandemic, an official said on Tuesday.

Read more
9 Dec 2020 12:57

People with severe allergies told to avoid Pfizer-BioNTech Covid vaccine

(Sharecast News) - People who have severe allergies should not receive the Pfizer-BioNTech Covid-19 vaccine, the UK regulator has announced.

Read more
11 Nov 2020 12:48

EU agrees deal for up to 300m doses of Pfizer's potential Covid-19 vaccine

(Sharecast News) - The European Union has finalised a deal with US drugs giant Pfizer to acquire up to 300m doses of its experimental Covid-19 vaccine, with delivery potentially starting as soon as December.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.